Soliris (eculizumab) / AstraZeneca |
| Completed | 2 | 1 | US, Europe | Eculizumab | Alexion Pharmaceuticals | Atypical Hemolytic Uremic Syndrome | 09/10 | 07/13 | | |
| Completed | 2 | 16 | US, Europe | Eculizumab | Alexion Pharmaceuticals | Atypical Hemolytic Uremic Syndrome | 09/10 | 07/13 | | |
| Completed | 2 | 5 | Canada, Europe | eculizumab | Alexion Pharmaceuticals | Atypical Hemolytic Uremic Syndrome | 10/10 | 12/13 | | |
| Completed | 2 | 15 | Canada, Europe | eculizumab | Alexion Pharmaceuticals | Atypical Hemolytic Uremic Syndrome | 10/10 | 12/13 | | |
NCT01757431: The Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS) |
|
|
| Completed | 2 | 2 | Japan | Eculizumab | Alexion Pharmaceuticals | Atypical Hemolytic Uremic Syndrome (aHUS) | 09/13 | 09/13 | | |
| Completed | 2 | 44 | US, Europe | Eculizumab | Alexion Pharmaceuticals | Atypical Hemolytic-Uremic Syndrome | 10/13 | 02/14 | | |
aHUS, NCT01193348: An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome |
|
|
| Completed | 2 | 22 | US, Canada, Europe, RoW | Eculizumab | Alexion Pharmaceuticals | Atypical Hemolytic-Uremic Syndrome | 01/14 | 04/14 | | |